Medicare To Cover Weight Loss Drug to Reduce Risk of Cardiovascular Disease

On March 21, 2024, the Centers for Medicare and Medicaid Services (CMS) announced that Wegovy, a prescription weight loss medication developed by Novo Nordisk, would now be eligible for coverage under Medicare Part-D for the specific use of reducing the risk of death attributable to cardiovascular disease in overweight or obese individuals.

For more information, contact:
Isabelle Bibet-Kalinyak, Vice Chair | 973.403.3131 | ibibetkalinyak@bracheichler.com
Michael C. Foster | 973.403.3102 | mfoster@bracheichler.com

*This is an informational podcast only and not intended to create an attorney-client relationship with the attendees.